CHARLES HOMCY, M.D.
Hospitals at Filbert St, San Francisco, CA
License number
California AH6412756
Category
Hospitals
Type
General Acute Care Hospital
Address
Address
1327 Filbert St, San Francisco, CA 94109
Phone
(415) 359-0179
Personal information
See more information about CHARLES HOMCY at radaris.comName
Address
Phone
1293 Canyon Rd, Geyserville, CA 95441
1327 Filbert St, San Francisco, CA 94109
256 Grand Ave, South San Francisco, CA 94080
2 Fallon Pl, San Francisco, CA 94133
Organization information
See more information about CHARLES HOMCY at bizstanding.comCharles Homcy
Geyserville, CA - San Francisco, CA
Status:
Inactive
Industry:
Business Services at Non-Commercial Site, Nonclassifiable Establishments, Internist
Doing business as:
Charles Homcy MD
Phone:
(415) 359-0179 (Phone)
Addresses:
1293 Cyn Rd, Geyserville, CA 95441
1327 Filbert St, San Francisco, CA 94109
1327 Filbert St, San Francisco, CA 94109
Principal:
Charles J. Homcy Principal, inactive
Professional information
See more information about CHARLES HOMCY at trustoria.com
President And Chief Executive Officer At Portola Pharmaceuticals, Inc.
President And Chief Executive Officer At Portola Pharmaceuticals, Inc.
Location:
San Francisco Bay Area
Industry:
Pharmaceuticals
Experience:
Portola Pharmaceuticals, Inc. (Privately Held; 51-200 employees; Biotechnology industry): President and Chief Executive Officer, (November 2003-Present) COR Therapeutics, Inc. (Pharmaceuticals industry): head, r and d, (1995-November 2003)
Transgenic Model Of Heart Failure
Transgenic Model Of Heart Failure
US Patent:
6333447, Dec 25, 2001
Filed:
Mar 29, 1996
Appl. No.:
8/627788
Inventors:
Charles C. Homcy - San Francisco CA
Stephen F. Vatner - Wayland MA
Thomas Wagner - Albany OH
Yoshihiro Ishikawa - Brookline MA
Stephen F. Vatner - Wayland MA
Thomas Wagner - Albany OH
Yoshihiro Ishikawa - Brookline MA
Assignee:
The General Hospital Corporation - Boston MA
Ohio University - Athens OH
The Presidents and Fellows of Harvard College - Cambridge MA
Ohio University - Athens OH
The Presidents and Fellows of Harvard College - Cambridge MA
International Classification:
C12N 1509, C12N 1563, C12N 1500, C12N 500
US Classification:
800 18
Abstract:
The present invention relates to transgenic models of heart failure and, more particularly, to transgenic animals and methods for testing the usefulness of chemical compounds in treating or preventing heart failure. A transgenic mouse was developed wherein G. sub. s. alpha. is selectively overexpressed approximately three-fold in the heart. Although steady state adenylyl cyclase activities are not altered, both the percent of agonist high affinity. beta. -adrenergic receptors as well as the rate of catalyst activation are increased. In addition, physiological and pathological studies revealed that chronically-facilitated sympathetic stimulation causes adverse cardiac effects.
Methods Of Treatment With Syk Inhibitors
Methods Of Treatment With Syk Inhibitors
US Patent:
8057815, Nov 15, 2011
Filed:
Apr 15, 2005
Appl. No.:
11/107324
Inventors:
Patrick Andre - San Mateo CA, US
David R. Phillips - San Mateo CA, US
Charles Homcy - San Francisco CA, US
David R. Phillips - San Mateo CA, US
Charles Homcy - San Francisco CA, US
Assignee:
Portola Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
A61F 2/02
US Classification:
424423
Abstract:
The present invention provides novel compositions and methods for inhibiting restenosis, thrombosis, and/or inflammation in a patient undergoing a vascular intervention. More particularly, the present invention provides intravascular devices coated with one or more spleen tyrosine kinase (Syk) inhibitors. Methods for inhibiting restenosis, thrombosis, and/or inflammation in a patient by treatment with such intravascular devices are also provided. In addition, the present invention provides methods for treating sickle cell disease using Syk inhibitors.
Methods Of Treatment With Syk Inhibitors
Methods Of Treatment With Syk Inhibitors
US Patent:
8470357, Jun 25, 2013
Filed:
Oct 5, 2011
Appl. No.:
13/253899
Inventors:
Patrick Andre - San Mateo CA, US
David R. Phillips - San Mateo CA, US
Charles Homcy - San Francisco CA, US
David R. Phillips - San Mateo CA, US
Charles Homcy - San Francisco CA, US
Assignee:
Portola Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
A61F 2/02
US Classification:
424423
Abstract:
The present invention provides novel compositions and methods for inhibiting restenosis, thrombosis, and/or inflammation in a patient undergoing a vascular intervention. More particularly, the present invention provides intravascular devices coated with one or more spleen tyrosine kinase (Syk) inhibitors. Methods for inhibiting restenosis, thrombosis, and/or inflammation in a patient by treatment with such intravascular devices are also provided. In addition, the present invention provides methods for treating sickle cell disease using Syk inhibitors.
Use Of Tp Modulators For The Treatment Of Cardiovascular Disorders In Aspirin Sensitive And Other Populations
Use Of Tp Modulators For The Treatment Of Cardiovascular Disorders In Aspirin Sensitive And Other Populations
US Patent:
2009001, Jan 8, 2009
Filed:
May 2, 2008
Appl. No.:
12/114642
Inventors:
David R. Phillips - San Mateo CA, US
Patrick Andre - San Mateo CA, US
Charles J. Homcy - San Francisco CA, US
Patrick Andre - San Mateo CA, US
Charles J. Homcy - San Francisco CA, US
Assignee:
Portola Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
A61K 31/4365, A61K 31/422, A61K 31/4406, A61K 31/18, A61K 31/444, A61K 31/192, A61K 31/403, A61P 9/00
US Classification:
514301, 514374, 514357, 514604, 514332, 514570, 514411, 514603
Abstract:
The present invention provides methods and compositions useful in the treatment or prevention of cardiovascular disorders in individuals for whom therapy with a COX-1 enzyme inhibitor is not feasible due to sensitivity, intolerance, or resistance to the inhibitor. Additionally, the invention provides methods of treating cardiovascular disorders in an individual who is receiving a therapeutically effective dose of a TP modulator and is instructed or advised to avoid and/or not to take aspirin or another COX-1 inhibitor.